The Australia biologics market was valued at USD 6.46 Billion in 2025 and is expected to grow at a CAGR of 5.70%, reaching USD 11.25 Billion by 2035. The market growth is driven by rising chronic disease burden, global investments, and expanding access to biologics across the region.
Base Year
Historical Period
Forecast Period
The market is anticipated to grow steadily due to rising healthcare needs and expanding biologic drug development supported by both public and private sector initiatives.
Increasing prevalence of chronic diseases and growing investment in innovative therapies are likely to strengthen Australia’s role in therapeutic biologics over the forecast period.
Strategic collaborations, biosimilar launches, and enhanced research capabilities are expected to drive the market, boosting Australia’s presence in the biologics pipeline industry.
Compound Annual Growth Rate
5.7%
Value in USD Billion
2026-2035
*this image is indicative*
The market experienced steady growth fueled by rising demand for advanced treatments targeting chronic and complex diseases. Increasing incidences of cancer and autoimmune disorders heightened the need for innovative biologic solutions, attracting global investments and strategic partnerships. Australia's robust healthcare infrastructure and focus on biologics industry trends strengthened its position as a key market for international players. The development of cutting-edge biologic therapies improved patient outcomes and accessibility, setting the stage for sustained market growth and evolving opportunities in the healthcare sector.
Rising Disease Burden Fueling Growth in the Australia Biologics Market
A growing burden of long-term health conditions was expected to be a major growth driver in the market, as demand surged for targeted and advanced therapies. For example, in June 2024, the Australian Institute of Health and Welfare (AIHW) reported that nearly 47% of Australians had at least one chronic condition, such as diabetes, cardiovascular disease, or arthritis. This rise in lifestyle-related illnesses increased reliance on biologic treatments for chronic conditions, encouraging innovation and investment in the Australian biologics space to meet evolving healthcare needs.
Global Investments Bolstering Growth in the Australia Biologics Market
A significant catalyst expected to drive momentum in the market is the increasing global investor confidence and capital flow toward cutting-edge biologic therapies. For example, in July 2025, GenSight Biologics secured EUR 5 million in financing to support its gene therapy programs. This move reflected rising interest in biologics manufacturing as companies worldwide expanded efforts to develop advanced treatment solutions. Such developments highlighted how innovation-backed funding laid the groundwork for future growth and collaboration opportunities in markets like Australia, attracting biotech firms and strategic partnerships.
The market is witnessing several emerging trends, including strategic collaborations, cross-border partnerships, and biosimilar product launches enhancing access to advanced biologic therapies.
Strategic Collaborations Shaping the Australia Biologics Market Value
In July 2025, Biocon Biologics partnered with Sandoz Australia to commercialize two key cancer biosimilars, trastuzumab and bevacizumab. This partnership reflected a growing trend of global companies joining forces to improve access to life-saving treatments in Australia. The collaboration highlighted the rising importance of biologic therapies in the oncology space, aligning with efforts to strengthen healthcare infrastructure and provide cost-effective solutions. Such alliances were expected to accelerate market growth and enhance treatment availability across the region.
International Partnerships Influencing the Australia Biologics Market
In December 2024, CSIRO reported that Australia and Thailand teamed up to improve equitable access to essential medicines through joint biologics research and development. This collaboration showcased a growing trend of cross-border partnerships aimed at strengthening regional healthcare systems. The initiative focused on expanding access to advanced biologic drugs for chronic diseases, supporting long-term affordability and innovation. Such alliances not only improved public health outcomes but also positioned Australia as a key player in shaping the future of global biologics development and distribution.
New Product Launches Propelling the Australia Biologics Market Expansion
In July 2025, Biocon Biologics announced the launch of NEPEXTO, a biosimilar to Enbrel (etanercept), in Australia. This moves enhanced access to advanced therapies and demonstrated the country’s growing focus on expanding biosimilar drugs to meet rising healthcare demands. Such developments positioned Australia as an attractive market for global biologics players seeking long-term growth and regional presence. This also signaled increased opportunities for collaboration, investment, and faster adoption of cost-effective biologic alternatives across the country.
Oncology to Dominate the Segmentation by Indication
Oncology is expected to lead the market share by indication due to the rising cancer burden in Australia. In June 2024, the Australian Institute of Health and Welfare (AIHW) estimated that around 169,000 cancer cases would be diagnosed, marking a 93% increase over 24 years. This rise was mainly due to population growth and an aging population, both of which increased cancer rates. The demand for advanced cancer biologics grew as personalized treatments became essential, driving significant market growth. Other segments included immunological disorders, cardiovascular disorders, hematological disorders, and others, which also supported market expansion.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Australia is a major biopharmaceutical player, supplying a broad portfolio of biologics that includes specialty treatments, oncology agents, vaccines, and COVID-19 immunisations—playing a key role in boosting Australia’s biologics sector. With significant local operations for clinical research and marketing, it contributes deeply to advanced biologic access, innovation, and healthcare delivery in Australia.
Novartis Australia is a leading provider of innovative biologics across oncology, immunology, and rare disease treatments, underpinned by strong local clinical development efforts. As a major multinational in the Australian biologics market, it supports tailored therapeutics and contributes to biopharma growth and patient access to advanced biologic therapies.
Roche Australia commands a significant position in the biologics market, especially through its focus on oncology, personalized medicine, and diagnostics-driven immunotherapies. With a strong presence in biopharmaceutical innovation and patient-centric treatments, Roche enhances Australia's capabilities in precision biologics and long-term therapeutic solutions.
Amgen Australia is a biotechnology leader in the country’s biologics landscape, particularly in oncology and inflammatory disease treatments, and is active in biosimilar initiatives and patient access programs. Its presence helps drive affordability, biosimilar adoption, and therapeutic innovation across Australia’s evolving biopharma market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Sanofi, Eli Lily and Company and Bristol-Myers Squibb Company.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Source
Market Breakup by Product
Market Breakup by Indication
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Source |
|
| Breakup by Product |
|
| Breakup by Indication |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share